Multiple Myeloma
March 2019 Issue

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Multiple Myeloma abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Multiple Myeloma. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Multiple Myeloma. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Multiple Myeloma every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content, Inc.

1:The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey.
Authors:Brioli A, Klaus M, Sayer H, Scholl S, Ernst T, Hilgendorf I, Scherag A, Yomade O, Schilling K, Hochhaus A, Mugge LO, von Lilienfeld-Toal M
Institution:Klinik fur Innere Medizin II, Abt. Hamatologie und Internistische Onkologie, Universitatsklinikum Jena, Jena, Germany.; Research Program 'Else Kroner-Forschungskolleg AntiAge', Universitatsklinikum Jena, Jena, Germany.; HELIOS Klinikum, 4. Medizinische Klinik, Abt. Hamatologie und internistische Onkologie, Hamostaseologie, Erfurt, Germany.; Integriertes Forschungs-und Behandlungszentrum (IFB) Sepsis und Sepsisfolgen, Center for Sepsis Control and Care (CSCC), Universitatsklinikum Jena, Jena, Germany.; Institut fur Medizinische Statistik, Informatik und Datenwissenschaften, Universitatsklinikum Jena, Jena, Germany.
Journal:Ann Hematol. 2019 Mar;98(3):713-722. doi: 10.1007/s00277-019-03621-1. Epub 2019 Jan 24.

2:Study of the frequency and reasons for discontinuation of different lines of treatment in patients with multiple myeloma.
Authors:Senin A, Garcia-Pallarols F, Ben Azaiz R, Martinez-Serra L, Montesdeoca S, Roman D, Ferraro M, Parraga I, Besses C, Abella E
Institution:Hematology Department, Hospital del Mar-IMIM (Institut Hospital del Mar d'Investigacions Mediques), Universidad Autonoma de Barcelona, Barcelona, Spain.
Journal:Ann Hematol. 2019 Mar;98(3):705-711. doi: 10.1007/s00277-019-03601-5. Epub 2019 Jan 23.

3:Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
Authors:Lei M, Feng H, Bai E, Zhou H, Wang J, Qin Y, Zhang H, Wang X, Liu Z, Hai O, Liu J, Zhu Y
Institution:College of Science, Nanjing Forestry University, No. 159 Longpan Road, Nanjing 210037, PR China.
Journal:Org Biomol Chem. 2019 Jan 16;17(3):683-691. doi: 10.1039/c8ob02668h.

4:Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.
Authors:Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, Cidado J, Embrey KJ, Gangl E, Gibbons FD, Gregory GP, Hargreaves D, Hendricks JA, Johannes JW, Johnstone RW, Kazmirski SL, Kettle JG, Lamb ML, Matulis SM, Nooka AK, Packer MJ, Peng B, Rawlins PB, Robbins DW, Schuller AG, Su N, Yang W, Ye Q, Zheng X, Secrist JP, Clark EA, Wilson DM, Fawell SE, Hird AW
Institution:Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA. Medicine, Atlanta, GA, 30322, USA.
Journal:Nat Commun. 2018 Dec 17;9(1):5341. doi: 10.1038/s41467-018-07551-w.

5:Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients.
Authors:Giralt S, Seifter E
Institution:Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; and.
Journal:Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):103-109. doi: 10.1182/asheducation-2018.1.103.

6:Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist.
Authors:Wildes TM, Anderson KC
Institution:Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO; and. Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Journal:Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):88-96. doi: 10.1182/asheducation-2018.1.88.

7:Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Authors:Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Feng L, Berkova Z, Hildebrandt M, Orlowski RZ
Institution:Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: Center, Houston, TX, USA. Center, Houston, TX, USA. Center, Houston, TX, USA. MD Anderson Cancer Center, Houston, TX, USA. Houston, TX, USA. Center, Houston, TX, USA. Houston, TX, USA. Center, Houston, TX, USA; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Journal:Lancet Haematol. 2018 Dec;5(12):e628-e640. doi: 10.1016/S2352-3026(18)30174-1.

8:Navigating the treatment landscape in multiple myeloma: which combinations to use and when?
Authors:Goldschmidt H, Ashcroft J, Szabo Z, Garderet L
Institution:Internal Medicine V and National Center for Tumor Diseases (NCT), University Clinic Heidelberg, 69120, Heidelberg, Germany. France. cellulaire, Sorbonne Universite, Paris 6, Paris, France.
Journal:Ann Hematol. 2019 Jan;98(1):1-18. doi: 10.1007/s00277-018-3546-8. Epub 2018 Nov 23.

9:Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials.
Authors:D'Agostino M, De Paoli L, Conticello C, Offidani M, Ria R, Petrucci MT, Spada S, Marcatti M, Catalano L, Gilestro M, Guglielmelli T, Baldini L, Gamberi B, Rizzi R, De Sabbata G, Di Renzo N, Patriarca F, Pezzatti S, Siniscalchi A, Ribolla R, Palumbo A, Montefusco V, Nagler A, Boccadoro M, Gay F
Institution:Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino, Italy. Electronic address:; AOU Maggiore della Carita Novara, Universita del Piemonte Orientale, Novara, Italy.; Divisione di Ematologia, AOU Policlinico-OVE, Catania, Italy.; Clinica di Ematologia, AOU Ospedali Riuniti di Ancona, Ancona, Italy.; University of Bari 'Aldo Moro' Medical School, Department of Biomedical Science, Internal Medicine 'G. Baccelli' Policlinico, Bari, Italy.
Journal:Crit Rev Oncol Hematol. 2018 Dec;132:9-16. doi: 10.1016/j.critrevonc.2018.09.008. Epub 2018 Sep 14.

10:Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma.
Authors:Castella M, Fernandez de Larrea C, Martin-Antonio B
Institution:Department of Hematology, Hospital Clinic, IDIBAPS, 08036 Barcelona, Spain.
Journal:Int J Mol Sci. 2018 Nov 15;19(11). pii: ijms19113613. doi: 10.3390/ijms19113613.

11:Ixazomib for the treatment of multiple myeloma.
Authors:Richardson PG, Zweegman S, O'Donnell EK, Laubach JP, Raje N, Voorhees P, Ferrari RH, Skacel T, Kumar SK, Lonial S
Institution:a Division of Hematologic Malignancy, Jerome Lipper Multiple Myeloma Center , Dana-Farber Cancer Institute , Boston , MA , USA. Amsterdam , Amsterdam , The Netherlands. MA , USA. Dana-Farber Cancer Institute , Boston , MA , USA. MA , USA. Institute, Atrium Health , Charlotte , NC , USA. USA. USA.
Journal:Expert Opin Pharmacother. 2018 Dec;19(17):1949-1968. doi: 10.1080/14656566.2018.1528229. Epub 2018 Nov 13.

12:Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
Authors:Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J
Institution:From the National and Kapodistrian University of Athens, Athens (M.A.D.); Karol Marcinkowski University of Medical Sciences, Poznan (D.D.), and Silesian Medical University, Katowice (S.G.) - both in Poland; University Hospital, Nantes (P.M.), and Centre Hospitalier Universitaire de Poitiers-La Miletrie, Poitiers (X.L.) - both in France; National Hospital Organization Disaster Medical Center (N.T.) and the Japanese Red Cross Medical Center (K.S.), Tokyo, and Ibaraki Prefectural Central Hospital, Kasama (M.H.) - all in Japan; Hopital Maisonneuve-Rosemont, University of Montreal, Montreal (R.L.); Heidelberg University Hospital, Heidelberg, Germany (M.S.R.); Dana-Farber Cancer Institute, Boston (P.G.R.); Bristol-Myers Squibb, Princeton, NJ (M.P.M., Y.-M.J., S.G.S., M.R., B.R.); and Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra (IDISNA), Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Pamplona, Spain (J.S.-M.).
Journal:N Engl J Med. 2018 Nov 8;379(19):1811-1822. doi: 10.1056/NEJMoa1805762.

13:Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma.
Authors:Marini C, Maia T, Bergantim R, Pires J, Aguiar E, Guimaraes JE, Trigo F
Institution:Centro Hospitalar de Sao Joao, Porto, Portugal.
Journal:Ann Hematol. 2019 Feb;98(2):369-379. doi: 10.1007/s00277-018-3528-x. Epub 2018 Oct 27.

14:Therapeutic antibodies for multiple myeloma.
Authors:Ishida T
Institution:Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Journal:Jpn J Clin Oncol. 2018 Nov 1;48(11):957-963. doi: 10.1093/jjco/hyy133.

15:Drug resistance in multiple myeloma.
Authors:Robak P, Drozdz I, Szemraj J, Robak T
Institution:Department of Experimental Hematology, Medical University of Lodz, Lodz, Poland. address:
Journal:Cancer Treat Rev. 2018 Nov;70:199-208. doi: 10.1016/j.ctrv.2018.09.001. Epub 2018 Sep 4.

16:Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects.
Authors:Gavazzoni M, Lombardi CM, Vizzardi E, Gorga E, Sciatti E, Rossi L, Belotti A, Rossi G, Metra M, Raddino R
Institution:Cardiology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health University, Cardiothoracic Department, Spedali Civili of Brescia, Italy. Electronic address:; Department of Hematology, Spedali Civili of Brescia, Brescia, Italy.
Journal:Eur J Pharmacol. 2018 Nov 5;838:85-90. doi: 10.1016/j.ejphar.2018.09.014. Epub 2018 Sep 7.

17:Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study.
Authors:Cella D, McKendrick J, Kudlac A, Palumbo A, Oukessou A, Vij R, Zyczynski T, Davis C
Institution:Northwestern University, Chicago, IL, USA.
Journal:Ann Hematol. 2018 Dec;97(12):2455-2463. doi: 10.1007/s00277-018-3469-4. Epub 2018 Sep 4.

18:Clinical significance of cancer-related fatigue in multiple myeloma patients.
Authors:Suzuki K, Kobayashi N, Ogasawara Y, Shimada T, Yahagi Y, Sugiyama K, Takahara S, Saito T, Minami J, Yokoyama H, Kamiyama Y, Katsube A, Kondo K, Yanagisawa H, Aiba K, Yano S
Institution:Department of Clinical Oncology/Hematology, The Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi, Minato-ku, Tokyo, 105-8461, Japan.; Department of Virology, The Jikei University School of Medicine, Tokyo, Japan.; Central Clinical Laboratory, The Jikei University Hospital, Tokyo, Japan.; Department of Public Health and Enviromental Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Journal:Int J Hematol. 2018 Dec;108(6):580-587. doi: 10.1007/s12185-018-2516-1. Epub 2018 Aug 28.

19:Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma.
Authors:Chehab S, Panjic EH, Gleason C, Lonial S, Nooka AK
Institution:Winship Cancer Institute, Emory University, Atlanta, GA, 30322, USA.
Journal:Future Oncol. 2018 Dec;14(30):3111-3121. doi: 10.2217/fon-2018-0275. Epub 2018 Aug 23.

20:Frontline treatment for transplant-eligible multiple myeloma: A 6474 patients network meta-analysis.
Authors:Sekine L, Ziegelmann PK, Manica D, da Fonte Pithan C, Sosnoski M, Morais VD, Falcetta FS, Ribeiro MR, Salazar AP, Ribeiro RA
Institution:Post-graduation Program in Epidemiology-Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. Sul, Porto Alegre, Brazil. Sul, Porto Alegre, Brazil.
Journal:Hematol Oncol. 2019 Feb;37(1):62-74. doi: 10.1002/hon.2552. Epub 2018 Sep 20.

21:The role of carfilzomib in treatment of newly diagnosed multiple myeloma.
Authors:Strifler S, Knop S
Institution:Department of Internal Medicine II, Division of Hematology & Medical Oncology, Wuerzburg University Medical Center, Wuerzburg, Germany. Wuerzburg University Medical Center, Wuerzburg, Germany.
Journal:Future Oncol. 2018 Dec;14(30):3123-3134. doi: 10.2217/fon-2018-0040. Epub 2018 Jul 30.

For a FREE PREVIEW of the Medifocus Guidebook on Multiple Myeloma click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Multiple Myeloma click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

Get the Medifocus Guidebook on Multiple Myeloma...
at a Special 20% Discount

Medifocus Guidebook on Multiple Myeloma

Updated: January 4, 2019
165 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
  • Timely, up to date content with free guidebook updates for 1 year.
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
  • Over 130,000 Guidebooks Sold
  • 100% Risk Free Money Back Guarantee


The Medifocus Guidebook on Multiple Myeloma is available in the following two convenient formats:


Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook


Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook

Order by Phone

Call Toll Free in the U.S.

From Outside the U.S.

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders


Coupon Expires: July 18, 2019

What Our Customers Are Saying...

"The information in your MediFocus Guidebook on Multiple Myeloma was extremely useful. Thank you for providing this service."
Milwaukee, Wisconsin

"I purchased the MediFocus Guidebook on Multiple Myeloma for my mother and it was a great help because it helped us to understand more about the disease, the causes, and the treatment options. Although there is no cure, it has helped us cope with the situation and helped us figure out how we can live with the disease."
New York, New York

"My oncologist borrowed my copy of the MediFocus Guidebook on Multiple Myeloma and found it very useful in his work. He intends to contact your office."
Miami Beach, Florida

Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2019 Medifocus, Inc. All rights reserved.